2000
Palliative care for HIV disease in the era of highly active antiretroviral therapy
Greenberg B, Mccorkle R, Vlahov D, Selwyn P. Palliative care for HIV disease in the era of highly active antiretroviral therapy. Journal Of Urban Health 2000, 77: 150-165. PMID: 10855997, PMCID: PMC3456123, DOI: 10.1007/bf02390527.Peer-Reviewed Original ResearchImproved Antioxidant Status Among HIV-Infected Injecting Drug Users on Potent Antiretroviral Therapy
Tang A, Smit E, Semba R, Shah N, Lyles C, Li D, Vlahov D. Improved Antioxidant Status Among HIV-Infected Injecting Drug Users on Potent Antiretroviral Therapy. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2000, 23: 321-326. DOI: 10.1097/00042560-200004010-00006.Peer-Reviewed Original ResearchConceptsHIV-positive IDUsHIV-negative IDUsAntiretroviral therapySerum antioxidant levelsLutein/zeaxanthinStudy subjectsART regimenAntioxidant levelsSerum levelsDrug usersProtease inhibitorsLow serum antioxidant levelsPotent antiretroviral therapyInjecting Drug UsersExcess oxidative stressOxidative stress levelsΒ-cryptoxanthinAlcohol intakeSerum antioxidantsDietary intakeAntioxidant statusSignificant overall differenceΑ-tocopherolSerum αDrug useImproved antioxidant status among HIV-infected injecting drug users on potent antiretroviral therapy.
Tang A, Smit E, Semba R, Shah N, Lyles C, Li D, Vlahov D. Improved antioxidant status among HIV-infected injecting drug users on potent antiretroviral therapy. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2000, 23: 321-6. PMID: 10836754, DOI: 10.1097/00126334-200004010-00006.Peer-Reviewed Original ResearchConceptsHIV-positive IDUsHIV-negative IDUsAntiretroviral therapySerum antioxidant levelsLutein/zeaxanthinStudy subjectsART regimenAntioxidant levelsSerum levelsDrug usersProtease inhibitorsLow serum antioxidant levelsSerum alpha-tocopherol levelsAlpha-tocopherolPotent antiretroviral therapyAlpha-tocopherol levelsExcess oxidative stressOxidative stress levelsAlcohol intakeSerum antioxidantsDietary intakeAntioxidant statusSignificant overall differenceDrug useHIV
1999
Evaluating supervised haart in late-stage HIV among drug users: A preliminary report
Greenberg B, Berkman A, Thomas R, Hoos D, Finkelstein R, Astemborski J, Vlahov D. Evaluating supervised haart in late-stage HIV among drug users: A preliminary report. Journal Of Urban Health 1999, 76: 468-480. PMID: 10609596, PMCID: PMC3456696, DOI: 10.1007/bf02351504.Peer-Reviewed Original ResearchConceptsInjection drug usersResidential health care facilitiesViral load increaseViral loadDrug usersMean age 42 yearsHepatitis C virus antibodyHuman immunodeficiency virus (HIV) infectionActive antiretroviral therapyC virus antibodyTreatment-experienced patientsImmunodeficiency virus infectionAge 42 yearsHistory of dementiaLate-stage HIVHealth care facilitiesHIV/AIDSHCV seropositivityAntiretroviral therapyInitial CD4IDU populationRecord reviewSupervised therapyVirus antibodiesMedication administration
1998
Self-reported Antiretroviral Therapy in Injection Drug Users
Celentano D, Vlahov D, Cohn S, Shadle V, Obasanjo O, Moore R. Self-reported Antiretroviral Therapy in Injection Drug Users. JAMA 1998, 280: 544-546. PMID: 9707145, DOI: 10.1001/jama.280.6.544.Peer-Reviewed Original ResearchMeSH KeywordsAnti-HIV AgentsCross-Sectional StudiesDrug Therapy, CombinationFemaleHIV InfectionsHumansMaleMultivariate AnalysisProtease InhibitorsSubstance Abuse, IntravenousConceptsHuman immunodeficiency virusInjection drug usersSelf-reported ART useAntiretroviral therapyART useDrug usersCombination therapyProtease inhibitorsRecent human immunodeficiency virusSelf-reported antiretroviral therapyInternational AIDS Society-USACurrent drug injectorsRecent antiretroviral therapyProtease inhibitor useHalf of patientsUS Public Health ServiceTriple combination therapyCommunity-based clinicsProportion of subjectsHealth care providersCurrent drug useActive drug usersCross-sectional surveyPublic health servicesInhibitor use